About the Project:

The STAR-T1D Study is a multi-site clinical trial aimed at improving outcomes for individuals with poorly controlled type 1 diabetes (T1D), defined as having an A1C of 8.5% or higher. This study specifically focuses on patients who are often considered less ideal candidates for insulin pump therapy due to clinical or social factors. Our clinical sites include UCLA Health and the Los Angeles County hospitals: Harbor-UCLA and Olive View-UCLA.

In this 6-month randomized controlled trial, 40 participants are enrolled to evaluate whether automated insulin delivery (AID) systems can lead to better glycemic control compared to standard diabetes care with structured education. In addition to clinical outcomes, the study incorporates qualitative interviews to explore the facilitators and barriers to adopting diabetes technology in a higher-risk population. The findings aim to inform more inclusive strategies for expanding access to advanced diabetes technologies.

Funding: NIH-NIDDK National Institute of Diabetes and Digestive and Kidney Diseases (K23DK132482)

Study Status: Recruiting

Recruitment Eligibility:

We are recruiting adult (18+) participants who:

• • Have had type 1 diabetes for at least one year
  • Have an A1c ≥ 8.5%
  • Use multiple daily insulin injections
  • Speak English or Spanish
  • Have medical insurance coverage

*Exclusions include pregnancy, significant cognitive impairment, limited life expectancy, or other factors that would interfere with study participation.

If you are interested in learning more about the study or believe you may qualify to take part in the study, please email STAR-T1D@mednet.ucla.edu or call/text (310) 882-0033 to speak with the study coordinator.